Sakar Healthcare Limited

NSEI:SAKAR Stok Raporu

Piyasa değeri: ₹6.8b

Sakar Healthcare Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 2/6

Sakar Healthcare yıllık ortalama 6.5% oranında kazançlarını artırırken, Pharmaceuticals sektöründe kazançlar growing at 13.4% annual. Gelirler growing yılda ortalama 14.5% oranında artmaktadır. Sakar Healthcare'in özkaynak karlılığı 4.6% ve net marjı 7.5%'dir.

Anahtar bilgiler

6.5%

Kazanç büyüme oranı

-1.7%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi17.5%
Gelir büyüme oranı14.5%
Özkaynak getirisi4.6%
Net Marj7.5%
Son Kazanç Güncellemesi30 Sep 2024

Yakın geçmiş performans güncellemeleri

Sakar Healthcare's (NSE:SAKAR) Anemic Earnings Might Be Worse Than You Think

Oct 30
Sakar Healthcare's (NSE:SAKAR) Anemic Earnings Might Be Worse Than You Think

Recent updates

Sakar Healthcare's (NSE:SAKAR) Anemic Earnings Might Be Worse Than You Think

Oct 30
Sakar Healthcare's (NSE:SAKAR) Anemic Earnings Might Be Worse Than You Think

Is Sakar Healthcare (NSE:SAKAR) A Risky Investment?

Dec 28
Is Sakar Healthcare (NSE:SAKAR) A Risky Investment?

Does Sakar Healthcare (NSE:SAKAR) Have A Healthy Balance Sheet?

Aug 05
Does Sakar Healthcare (NSE:SAKAR) Have A Healthy Balance Sheet?

Is Sakar Healthcare (NSE:SAKAR) A Risky Investment?

Mar 29
Is Sakar Healthcare (NSE:SAKAR) A Risky Investment?

Here's Why Sakar Healthcare (NSE:SAKAR) Has Caught The Eye Of Investors

Jan 31
Here's Why Sakar Healthcare (NSE:SAKAR) Has Caught The Eye Of Investors

Is Sakar Healthcare (NSE:SAKAR) Using Too Much Debt?

Dec 01
Is Sakar Healthcare (NSE:SAKAR) Using Too Much Debt?

Sakar Healthcare (NSE:SAKAR) Has A Somewhat Strained Balance Sheet

Jul 13
Sakar Healthcare (NSE:SAKAR) Has A Somewhat Strained Balance Sheet

Sakar Healthcare (NSE:SAKAR) Has A Somewhat Strained Balance Sheet

Mar 26
Sakar Healthcare (NSE:SAKAR) Has A Somewhat Strained Balance Sheet

With EPS Growth And More, Sakar Healthcare (NSE:SAKAR) Is Interesting

Jul 01
With EPS Growth And More, Sakar Healthcare (NSE:SAKAR) Is Interesting

Here's Why I Think Sakar Healthcare (NSE:SAKAR) Might Deserve Your Attention Today

Mar 23
Here's Why I Think Sakar Healthcare (NSE:SAKAR) Might Deserve Your Attention Today

Insider Buying: The Sakar Healthcare Limited (NSE:SAKAR) Chairman & MD Just Bought 7.1% More Shares

Mar 02
Insider Buying: The Sakar Healthcare Limited (NSE:SAKAR) Chairman & MD Just Bought 7.1% More Shares

Has Sakar Healthcare Limited's (NSE:SAKAR) Impressive Stock Performance Got Anything to Do With Its Fundamentals?

Feb 08
Has Sakar Healthcare Limited's (NSE:SAKAR) Impressive Stock Performance Got Anything to Do With Its Fundamentals?

Does Sakar Healthcare (NSE:SAKAR) Have A Healthy Balance Sheet?

Jan 10
Does Sakar Healthcare (NSE:SAKAR) Have A Healthy Balance Sheet?

Here's Why I Think Sakar Healthcare (NSE:SAKAR) Is An Interesting Stock

Dec 14
Here's Why I Think Sakar Healthcare (NSE:SAKAR) Is An Interesting Stock

Should You Rely On Sakar Healthcare's (NSE:SAKAR) Earnings Growth?

Nov 22
Should You Rely On Sakar Healthcare's (NSE:SAKAR) Earnings Growth?

Gelir ve Gider Dağılımı

Sakar Healthcare nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.


Kazanç ve Gelir Geçmişi

NSEI:SAKAR Gelir, gider ve kazançlar (INR Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
30 Sep 241,6501242060
30 Jun 241,5551121980
31 Mar 241,5421171990
31 Dec 231,5181252010
30 Sep 231,4801442030
30 Jun 231,4381271890
31 Mar 231,3421281690
31 Dec 221,3021781690
30 Sep 221,2651391550
30 Jun 221,2651441520
31 Mar 221,2911521540
31 Dec 211,139801310
30 Sep 211,109971330
30 Jun 211,0541181340
31 Mar 219531071330
31 Dec 209131181370
30 Sep 208701221320
30 Jun 208841061300
31 Mar 20839961230
31 Dec 19851881140
30 Sep 19844861120
30 Jun 1974478980
31 Mar 1968867910
31 Mar 1853438690
31 Mar 1744734600
31 Mar 1641422500
31 Dec 1538624490
31 Mar 1535018400
31 Mar 1429718330

Kaliteli Kazançlar: SAKAR yüksek kaliteli kazançlar sağlıyor.

Büyüyen Kar Marjı: SAKAR 'nin mevcut net kar marjları (7.5%) geçen yılın (9.7%) değerinden daha düşüktür.


Serbest Nakit Akışı ve Kazanç Analizi


Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: SAKAR şirketinin kazancı son 5 yılda yılda 6.5% oranında arttı.

Büyüme Hızlandırma: SAKAR 'in son bir yıldır negatif kazanç büyümesi oldu, bu nedenle 5 yıllık ortalamasıyla karşılaştırılamaz.

Kazançlar vs. Sektör: SAKAR geçtiğimiz yıl negatif kazanç büyümesine ( -13.9% ) sahipti ve bu da onu Pharmaceuticals sektör ortalamasıyla ( 19.1% ) karşılaştırmayı zorlaştırıyordu.


Özkaynak Getirisi

Yüksek ROE: SAKAR 'nin Özsermaye Getirisi ( 4.6% ) düşük olarak değerlendiriliyor.


Varlık Getirisi


Kullanılan Sermaye Getirisi


Geçmişte güçlü performans gösteren şirketleri keşfedin